New drug approved for OFF episodes

Today, Neurocrine Biosciences announced that the Food and Drug Administration (FDA) approved ONGENTYS ® (opicapone), a new medication for...see more treatment of Parkinson’s disease (PD). Opicapone is a catechol-O-methyltransferase (COMT) inhibitor to be used once-daily as an add-on treatment to levodopa for patients who are experiencing OFF time with their current medication regimen. Opicapone is in […]

Read More

CORONAVIRUS DISEASE 2019 AND THE PD COMMUNITY

APDA COVID-19 INFORMATION & RESOURCES: The American Parkinson Disease Association (APDA) continues to monitor the COVID-19 situation, particularly as...see more it relates to our Parkinson’s disease (PD) community. This page is updated regularly as new information becomes available. Vaccines: Three COVID-19 vaccines have been approved for use in the United States — one manufactured by Pfizer/BioNTech, […]

Read More

The 26th Annual Parkinson’s Unity Walk

The American Parkinson Disease Association (APDA) is a proud partner of the 26th Annual Parkinson’s Unity Walk taking place on...see more Saturday, April 25, 2020 in Central Park, New York City. 100% of donations raised by the event will go to research funded by the leading PD foundations, including APDA. In addition to raising awareness and funds […]

Read More